PMV Pharma Reports Strong Clinical Data for Lead Cancer Drug Rezatapopt, Confirms NDA Timeline, and Extends Cash Runway
Summary
PMV Pharmaceuticals reported Q1 2026 financial results, highlighted strong Phase 2 clinical data for rezatapopt in ovarian cancer, announced its publication in the New England Journal of Medicine, and confirmed its cash runway to Q2 2027.
Key Events
-
Strong Phase 2 Clinical Data
Rezatapopt showed an Overall Response Rate (ORR) of 44% (32/72 patients) per investigator assessment, increasing to 46% (34/74) post-data cutoff, with a median Duration of Response (DoR) of 8.2 months in platinum-resistant/refractory ovarian cancer patients.
-
Prestigious Publication
Phase 1 results from the PYNNACLE study were published in the New England Journal of Medicine, highlighting rezatapopt's antitumor activity and proof-of-concept for p53 reactivation.
-
NDA Submission on Track
The company anticipates submitting a New Drug Application (NDA) for rezatapopt in platinum-resistant/refractory ovarian cancer in the first quarter of 2027.
-
Orphan Drug Designation Confirmed
Rezatapopt was granted Orphan Drug Designation by the FDA for the treatment of TP53 Y220C positive ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.
Analysis
This filing provides a significant update on PMV Pharma's lead oncology candidate, rezatapopt, including positive Phase 2 clinical trial results (44-46% ORR, 8.2 months DoR) for platinum-resistant/refractory ovarian cancer, which is crucial for its registrational pathway. The publication in the New England Journal of Medicine adds substantial scientific validation. Furthermore, the company confirmed a cash runway to Q2 2027, providing financial stability for its ongoing development efforts.
At the time of this filing, PMVP was trading at $1.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.1M. The 52-week trading range was $0.81 to $1.88. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.